The reclassification reduces regulatory risk and shortens the timeline to a potential November 10, 2026 PDUFA/GDUFA decision. Traders should monitor for FDA action around that date and any subsequent commercial launch updates for NRX-100.
Drug in focus
NRXP drug pipeline →Preservative-Free Ketamine
◆ Mixed Named in this 8-K- Impact
- Phase
- Approved (ANDA)
- Time to market
- Approved as of October 30, 2026. The company has ordered 5 million vials for launch inventory and is transitioning to commercial-stage operations.
- Next catalyst
- None dated
What to watchThe ANDA approval binary has passed. Watch for commercial launch execution (hospital formulary adoption, initial sales numbers) and the Q3 2026 earnings call on November 16 for revenue guidance. The bigger binary catalyst ahead is the NRX-100 NDA decision for suicidal depression (estimated PDUFA ~December 2026), which targets a much larger market opportunity than the generic ANDA product. Also monitor the FDA's decision on NRx's citizen petition to ban BZT-containing ketamine products, which could dramatically alter the competitive landscape.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 16 $3.35entry
- T+1 · 2mo ago +1.19%α +0.06% · $3.39
- T+5 · 8w ago −5.67%α −8.24% · $3.16
- T+20 · 5w ago −19.40%α −22.58% · $2.70
- T+43 · todayOpen
- T+60 · in 23d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
NRx Pharmaceuticals announced that the FDA reclassified its ANDA amendment for preservative-free ketamine (NRX-100) from a Major Amendment to a Minor Amendment, pulling the GDUFA goal date forward to November 10, 2026. This regulatory de-escalation signals a lower review burden and accelerates the timeline toward potential approval of a drug-shortage product, a modest but positive catalyst for a clinical-stage biopharma with a $147M market cap.
Key Facts
- FDA reclassified NRx's ANDA amendment from Major to Minor Amendment.
- GDUFA goal date revised to November 10, 2026.
- FDA cited the reclassified amendment will not require a substantial expenditure of resources.
- Product is preservative-free ketamine (NRX-100), designated a drug shortage product.
- NRX-100 has Fast Track Designation for suicidal ideation in depression.
Financial Impact
No financial figures provided; regulatory milestone accelerates potential market entry for a drug-shortage product.
Risk Factors
- FDA may still issue a Complete Response Letter (CRL) at the goal date.
- Company remains clinical-stage with no approved products; cash runway and commercial execution are unproven.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-030492 |
| Exhibit: ex_1016862.htm | 0001437749-26-030492 |
| Document: 0001437749-26-030492-index-headers.html | 0001437749-26-030492 |
| Document: 0001437749-26-030492-index.html | 0001437749-26-030492 |
| Document: 0001437749-26-030492.txt | 0001437749-26-030492 |
Track record
22 reports on NRXP
8 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +70.33% at T+60 after the Mar 30, 2026 report. 9 of 12 went positive at some point.
Filters
- Nov 5, 202611d ago DEFA14A Neutral 3/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 5, 202611d ago DEF 14A Neutral 4/10 Entry $2.38 to $2.19 Now $2.15 −9.66% ▼ −7.98% −10.58% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $2.17 to $2.38 Now $2.15 −0.92% ▲ +9.68% +9.60% vs SPY
- Oct 30, 202617d ago Press Release Bullish 7/10 Entry $2.27 to $2.38 Now $2.15 −5.29% ▲ +4.85% +7.55% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $2.63 to $2.52 Now $2.15 −18.25% ▼ −4.18% −4.04% vs SPY
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $2.94 to $2.70 Now $2.15 −26.87% ▼ −8.16% −8.02% vs SPY
- Sep 15, 20268w ago 8-K Bullish 5/10 Viewing Entry $3.35 to $3.16 Now $2.15 −35.82% ▼ −5.67% −8.24% vs SPY
- Sep 14, 20269w ago 8-K Neutral 2/10 Entry $3.49 to $3.29 Now $2.15 −38.40% ▼ −5.73% −5.84% vs SPY
- Aug 17, 202613w ago 8-K Bullish 7/10 Entry $3.43 to $3.45 Now $2.15 −37.32% ▲ +0.58% +1.77% vs SPY
- Aug 17, 202613w ago Press Release Neutral 1/10 Entry $3.43 Now $2.15 −37.32% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers